Khosla Ventures has gone back in on Even Healthcare, taking the company’s total raised past $120 million for a model built to attack the economics of Indian hospitals. The repeat participation is the signal worth reading. A fund doubling down is making a narrower and more informative statement than a fund entering, because it has already watched the thesis survive contact with a market where a great many healthcare theses have not.
The problem being attacked is one of the clearest in global health finance. Indian healthcare is dominated by payment at the point of crisis. Routine care is mostly deferred because it comes out of pocket and feels optional, which means conditions that could have been managed cheaply for years present late, acute and expensive. At that point the patient enters a hospital whose entire revenue model is built around exactly that arrival. Beds, procedures, diagnostics and inpatient days are what gets billed, so the system’s income is structurally tied to people being very unwell rather than to people staying well. Nobody designed that perversity deliberately. It is simply what emerges when the money only moves at the sharp end.
Anyone who has drunk a truly bad coffee and then paid for a good one understands the arbitrage. Cheap coffee is not cheap. You buy it twice because the first one did not work, you add sugar and milk to make it tolerable, you drink it without pleasure and you are tired again within the hour. The good cup costs more on the receipt and less in total, because one of them does the job. The worst value in the entire category is the thing that looks free at the moment of decision and charges you repeatedly afterwards. Deferred healthcare is that arrangement at national scale, with the follow-up charges arriving in a hospital rather than at a counter.
Even’s answer, structurally, is to put the money at the front instead of the back. Charge a predictable recurring amount, make primary and preventive care genuinely accessible under it, and then own enough of the patient journey that keeping people out of hospital is your own financial interest rather than someone else’s inconvenience. It is a managed-care logic, and the reason it is hard in India is that it requires solving two problems simultaneously. You have to convince households to pay for care before they feel sick, which is a behavioural problem, and you have to control the cost of the care you have promised, which is a network and clinical problem. Companies that solve only the first become expensive insurance. Companies that solve only the second become a clinic chain with no demand engine.
Getting past $120 million raised suggests the company has at least established that both halves can be run together, which in this category is the real milestone. The economics only work when enough covered members exist to make the cost of avoided hospitalisation visible in aggregate, and that threshold is high. Below it, every expensive case looks like a disaster. Above it, the same case looks like a known rate.
What makes the position commercially interesting beyond the health outcome is who ends up holding the relationship. In the existing arrangement, the hospital owns the patient only at the moment of maximum distress, and has no contact before or after. A model that holds a continuous relationship owns the data, the diagnostics referral, the medication pathway and the trust, which is a considerably more valuable asset than a bed. It also makes the incumbent’s revenue line the new entrant’s cost line, which is the kind of head-on conflict that tends to produce either a durable business or a very instructive failure.
The cheapest healthcare in the world is the appointment nobody made, right up until the itemised printout arrives and keeps unrolling across the counter.
